Please provide your email address to receive an email when new articles are posted on . Riociguat treatment significantly improved exercise capacity and prevented clinical worsening in patients with ...

"This study revealed that exertional dyspnea, exertional palpitations, and decreased nailfold capillary density (≤ seven/mm) serve as useful indicator for considering exercise [right heart ...

In treatment-naïve patients with PAH, initial monotherapy improves exercise capacity, hemodynamics, and outcomes when compared with those noted among untreated patients. In patients who are newly ...

March 6 (Reuters) - Merck & Co Inc (MRK.N), opens new tab said on Monday its experimental therapy helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood ...

Poor sleep quality in PAH patients is linked to increased dyspnea and reduced exercise capacity, worsening disease burden. Severe dyspnea is a significant predictor of poor sleep quality, independent ...

Merck (NYSE:MRK) is approaching phase 2 data for Winrevair in pulmonary hypertension. Results will focus on the 6 minute walk ...